Reuters: Israel's largest bank reports Q1 net profit of NIS 192 million ($54 million) vs NIS 821 million a year earlier; shares slide 1.9% in morning trade, in line with market

Strong results due to greater demand for generic and OTC products and respiratory products, says pharmaceutical firm president and CEO Kåre Schultz

Reuters: World’s largest generic drugmaker earned 60 cents per diluted share, down from 94 cents a year earlier; says on track to cut $3 billion in costs by the end 2019

Reductions will come across all business units and regions; the firm plans to invest in innovation for its key products and expand sales efforts in key markets